T/FIF Portfolio Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF Portfolio

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (787)	4/12/1999 2:39:00 PM
From: Biotech Jim	Read Replies (2) of 1073

It is easier to respond to your query concerning sibutramine than axokine. I will put together my thoughts later (hopefully tonight) on axokine, though you must realize that this is quite a complex issue. As to sibutramine, I have followed this quite closely. I am a bit surprised that that there is so much excitement in the SEPR camp on this due to the elevated blood pressure and increased heart rate of the drug in the trials performed to date. Can you imagine being obese, with an already elevated blood pressure, and have these "side effects". Of course it is possible that they may have evidence to suggest that the side effects are related to the "off" enantiomer, or that efficacy of the different endpoints (feeding vs. cardiovascular) may be different. Is this so? Do you have any further insight into this? TIA BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next